Mohamed Emam Sobeih, Council Member at European School of Oncology College, Consultant of Medical Oncology at NCI Egypt, Founder of ECOC, shared a post on LinkedIn:
“Rezatapopt is an investigational, first-in-class, oral, selective small molecule p53 reactivator that binds specifically to Y220C-mutated p53. In a phase I, single-group, multicentre, dose-escalation and dose-optimization PYNNACLE study, rezatapopt activity was assessed in heavily pretreated patients with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation.”
Other articles about Y220C Mutation on OncoDaily.